# ğŸ“… Daily Report - 2025-11-19

> ä»Šæ—¥ç­›é€‰å‡º **109** æ¡å†…å®¹ï¼Œæ¥è‡ª **3** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ“° å…¬ä¼—å·

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
è…¾è®¯å‘å¸ƒscTranslatorï¼Œé¦–æ¬¡å®ç°å•ç»†èƒè½¬å½•ç»„åˆ°è›‹ç™½è´¨ç»„çš„AIç¿»è¯‘ï¼›Scienceå‘è¡¨é¦–ä¸ªå¤§è§„æ¨¡äººç±»é€ è¡€å•ç»†èƒè›‹ç™½è´¨ç»„å›¾è°±ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- è‚¿ç˜¤è½¬ç§»æ–°æœºåˆ¶ä¸æ²»ç–—ç­–ç•¥ï¼ˆåŒ…æ‹¬ä»£è°¢è°ƒæ§ã€KRAS/EGFRè€è¯ã€æ ‘çªçŠ¶ç»†èƒä½œç”¨ï¼‰
- å…ç–«æ²»ç–—æ–°é¶ç‚¹ä¸æ–¹æ³•ï¼ˆTRAP1ã€é€šç”¨å‹ç™Œç—‡ç–«è‹—ã€å…‰æ§ç„¦äº¡å…ç–«ã€DNAä¿®å¤ä¸å…ç–«æ¿€æ´»ç»“åˆï¼‰
- ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰çš„ç©ºé—´ç»„å­¦åˆ†æåŠé¢„åé¢„æµ‹
- ç¥ç»é€€è¡Œæ€§ç–¾ç—…çš„å…ç–«å¼‚å¸¸ä¸åˆ†å­è½¨è¿¹

**æŠ€æœ¯äº®ç‚¹**ï¼š
- scTranslatorï¼šAIå¤§æ¨¡å‹å®ç°å•ç»†èƒè½¬å½•ç»„åˆ°è›‹ç™½è´¨ç»„çš„ç¿»è¯‘ã€‚
- æ–°å‹ç©ºé—´ç»„å­¦è½¯ä»¶ï¼šæå‡å¤šç»„å­¦åˆ†ææ•ˆç‡ã€‚
- å¤šç»„å­¦ç©ºé—´å…ç–«è°±åˆ†æï¼šæ·±å…¥è§£æTLSäºšç¾¤ã€‚

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
é¦–æ¬¡å¯¹æ–°å‹å•ç»†èƒRNAæµ‹åºå¹³å°è¿›è¡Œæ¯”è¾ƒç ”ç©¶ï¼Œè¯„ä¼°å…¶ä¸10x Genomicsçš„æ€§èƒ½ï¼›æ­ç¤ºRBæ¿€æ´»åœ¨ä¸‰é˜´æ€§ä¹³è…ºç™Œä¸­è¯±å¯¼çš„è‚¿ç˜¤å’ŒåŸºè´¨æŠ—è‚¿ç˜¤ååº”ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
* æ¢ç´¢å·¨å‹ç—…æ¯’å¦‚ä½•é€šè¿‡åˆ›å»ºäºšç»†èƒç¯å¢ƒå…‹æœå¯†ç å­-tRNAå¤±é…ã€‚
* é‰´å®šB3GALT2ä¸ºæ–°çš„ç»†èƒASOæ´»æ€§è¯±å¯¼å‰‚ã€‚
* ç ”ç©¶NAT10é€šè¿‡è°ƒèŠ‚p300/CBPæ´»æ€§ä¿ƒè¿›ç™Œç—‡è½¬ç§»ã€‚
* é˜æ˜è„±æ°§æ ¸è‹·æ¿€é…¶ç¼ºä¹å¦‚ä½•å°†å˜Œå‘¤ä»£è°¢ä¸è‚ç»†èƒå…ˆå¤©å…ç–«æ¿€æ´»å’Œè„‚è´¨ç§¯ç´¯è”ç³»èµ·æ¥ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
* å¼€å‘å¹¶åº”ç”¨äºæ–°å‹æ¶²æ»´å¼å•ç»†èƒRNAæµ‹åºå¹³å°ã€‚
* æ„å»ºç”±å·ç§¯ç¥ç»ç½‘ç»œå¢å¼ºçš„åŠŸèƒ½åŸºå› ç»„å›¾è°±ï¼Œç”¨äºè§£æéç¼–ç åŒºç–¾ç—…ç›¸å…³å˜å¼‚ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š

*   **Foli-seqï¼šéä¾µå…¥æ€§è‚ é“å…ç–«ç›‘æµ‹æ–°æ–¹æ³•**
*   **CRISPRæŠ€æœ¯çªç ´ï¼šé‡å¡‘è€è¯æ€§è‚ºç™ŒåŒ–ç–—æ•æ„Ÿæ€§**

**ä¸»è¦æ–¹å‘**ï¼š

*   **è‚ é“å¥åº·ä¸ç‚ç—‡ç ”ç©¶**ï¼šåˆ©ç”¨è„±è½ç»†èƒè¿›è¡ŒRNAæµ‹åºï¼Œå®ç°å¯¹è‚ é“å…ç–«æ´»æ€§çš„éä¾µå…¥æ€§ç›‘æµ‹ã€‚
*   **è€è¯æ€§è‚ºç™Œæ²»ç–—**ï¼šé€šè¿‡CRISPRæŠ€æœ¯é¶å‘å¤±æ´»NRF2åŸºå› ï¼Œæ¢å¤åŒ–ç–—æ•æ„Ÿæ€§ï¼Œå»¶ç¼“è‚¿ç˜¤ç”Ÿé•¿ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š

*   **Foli-seq**ï¼šé¦–æ¬¡å°†RNAæµ‹åºåº”ç”¨äºç²ªä¾¿è„±è½ç»†èƒï¼Œæ‰©å±•äº†å¯¹è‚ é“å¥åº·å’Œç‚ç—‡çš„éä¾µå…¥æ€§ç ”ç©¶èŒƒç•´ã€‚
*   **CRISPRå¤±æ´»NRF2**ï¼šåœ¨è€è¯æ€§è‚ºç™Œç»†èƒä¸­ï¼Œé€šè¿‡CRISPRæŠ€æœ¯æˆåŠŸé€†è½¬äº†åŒ–ç–—è€è¯æ€§ï¼Œå³ä½¿åœ¨è‚¿ç˜¤ç»†èƒä¸­ä»…æœ‰éƒ¨åˆ†è¢«ç¼–è¾‘çš„æƒ…å†µä¸‹ä¹Ÿæœ‰æ•ˆã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (60æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **è…¾è®¯å‘è¡¨æœ€æ–°Natureå­åˆŠè®ºæ–‡ï¼šæ¨å‡ºAIå¤§æ¨¡å‹ï¼Œä»å•ç»†èƒè½¬å½•ç»„ç¿»è¯‘å•ç»†èƒè›‹ç™½è´¨ç»„**
- âœï¸ **ä½œè€…**ï¼šç”Ÿç‰©ä¸–ç•Œ
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€è½¬å½•ç»„ã€è›‹ç™½è´¨ç»„ã€ç»„è›‹ç™½
- ğŸ“ **æè¿°**ï¼šscTranslatorï¼ˆå•ç»†èƒç¿»è¯‘å™¨ï¼‰
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789365&idx=2&sn=18031e9ab6c7e30aa8f363c0420e9da3)

**2.** â­ **Nat Med | APOE Îµ4 ä»‹å¯¼çš„å…ç–«å¼‚å¸¸ï¼šç¥ç»é€€è¡Œæ€§ç–¾ç—…çš„å…±åŒåˆ†å­è½¨è¿¹**
- âœï¸ **ä½œè€…**ï¼šäººä½“è›‹ç™½è´¨ç»„å¯¼èˆªè®¡åˆ’
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€ç¥ç»ã€è½¨è¿¹
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&mid=2247507348&idx=3&sn=9a9747c0d69a76c29c9bae14480d3a71)

**3.** â­ **å›½è‡ªç„¶å‰æ²¿ï¼šè‚¿ç˜¤è½¬ç§»çš„ä»£è°¢â€œå¯†é’¥â€ï¼Œå¦‚ä½•æ”¹å†™ç™Œç—‡ç»“å±€ï¼Ÿ**
- âœï¸ **ä½œè€…**ï¼šåŒåŒ»æµäº‘Medfocus
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç™Œç—‡ã€ä»£è°¢
- ğŸ“ **æè¿°**ï¼šæ¶æ€§è‚¿ç˜¤çš„è¿œå¤„è½¬ç§»å¾€å¾€é¢„ç¤ºç€è¾ƒå·®çš„ä¸´åºŠç»“å±€ã€‚å½“ç™Œç»†èƒè„±ç¦»åŸå‘ç¶å‘å…¶ä»–ç»„ç»‡æ‰©æ•£æ—¶ï¼Œä¼šç»å†å¤æ‚çš„å¾®ç¯å¢ƒé€‚åº”è¿‡ç¨‹ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247487326&idx=2&sn=fe23dab9260419bfca9806139e02e9b7)

**4.** **IF:7.6ï¼åç§‘å¤§å›¢é˜Ÿå‘ç°LXR-Î²é€šè¿‡STAT6æ¿€æ´»å°èƒ¶ï¼Œå±äºç¥ç»ç‚ç—‡+å…ç–«ç»†èƒé€‰é¢˜**
- âœï¸ **ä½œè€…**ï¼šç¥ç»å²›
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€ç¥ç»
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkyNzcxMjEyMg==&mid=2247497933&idx=1&sn=71326c938c0b67d034fa9876ba650f2d)

**5.** **æœ€æ–°8+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦è¯†åˆ«ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰ç»“æ„å¹¶è¿›è¡Œé’ˆå¯¹æ€§åˆ†æã€‚é¢„æµ‹é¢„ååŠå…ç–«æ²»ç–—ç–—æ•ˆï¼Œå€¼å¾—å€Ÿé‰´ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503973&idx=4&sn=56422e6b9cbcc043c588a66d018cabc5)

**6.** **10æœˆæœ€æ–°26+ç”Ÿä¿¡ï¼Œå¤šç»„å­¦ç©ºé—´å…ç–«è°±åˆ†æç¡®å®šäº†ä¸‰çº§æ·‹å·´ç»“æ„ï¼ˆTLSï¼‰çš„äºšç¾¤å¹¶è¿›è¡Œæ·±å…¥åˆ†æï¼Œå»ºè®®æ”¶è—ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå…ç–«ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503973&idx=3&sn=3a656fb1373701d47ba036ec7a7d8f8e)

**7.** **æœ€æ–°8åˆ†ç”Ÿä¿¡ï¼Œç©ºè½¬å¤šç»„å­¦åˆ†ææ­ç¤ºCAF-ç™Œç»†èƒé€šè®¯ä»‹å¯¼ PARPi è€è¯çš„å…¨æ–°æœºåˆ¶ï¼Œå†…å®¹å¾ˆå°‘ï¼Œä¼˜åŠ¿åœ¨äºè‡ªæµ‹æ•°æ®ï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè€è¯ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šè¿™ç¯‡å‘è¡¨äºã€Šnpj Precision Oncologyã€‹çš„ç ”ç©¶ï¼Œèšç„¦é«˜ç­‰çº§æµ†æ¶²æ€§åµå·¢ç™Œï¼ˆHGSOCï¼‰å¯¹èšè…ºè‹·
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503973&idx=2&sn=349e923d3bf35055652d7b1eae019cb9)

**8.** **Nat Methods | æ–°å‹ç©ºé—´ç»„å­¦è½¯ä»¶åŠ©åŠ›ç™Œç—‡ç­‰å¤šç»„å­¦åˆ†ææ›´é«˜æ•ˆ**
- âœï¸ **ä½œè€…**ï¼šå›¾çµåŸºå› 
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€ç©ºé—´ç»„å­¦
- ğŸ“ **æè¿°**ï¼šçº½çº¦è¥¿å¥ˆå±±ä¼ŠååŒ»å­¦é™¢ã€æ³¢å£«é¡¿åŒ»ç–—ä¸­å¿ƒä¸æ³¢å£«é¡¿å¤§å­¦åŒ»å­¦é™¢çš„ç ”ç©¶äººå‘˜è”åˆå¼€å‘äº†ä¸€æ¬¾æ–°å‹è½¯ä»¶ï¼Œæ—¨åœ¨å¸®åŠ©ç§‘å­¦å®¶æ›´ä¾¿æ·åœ°åˆ†æå¥åº·ä¸ç–¾ç—…çŠ¶æ€ï¼ˆåŒ…æ‹¬ç™Œç—‡å’Œç¥ç»é€€è¡Œæ€§ç–¾ç—…ï¼‰ä¸‹ç»„ç»‡çš„åˆ†å­ç»“æ„ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&mid=2247555079&idx=2&sn=d5a2615b41a48ba448f1258b91621a0f)

**9.** **Natureé‡ç£…ï¼è§£æç™Œç—‡å…ç–«ä¸­çš„æ ‘çªçŠ¶ç»†èƒ**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡äºº
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€å…ç–«
- ğŸ“ **æè¿°**ï¼šæ ‘çªçŠ¶ç»†èƒæ˜¯è¿æ¥innate å…ç–«ï¼ˆå…ˆå¤©å…ç–«ï¼‰å’Œadaptive å…ç–«ï¼ˆé€‚åº”æ€§å…ç–«ï¼‰çš„å…³é”®æ¢çº½ï¼Œåœ¨è‚¿ç˜¤å…ç–«ä¸­æ—¢
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248522&idx=8&sn=0f1b016a289a08e18e99b511a63974a8)

**10.** **Cancer Cellçªç ´ç»¼è¿°ï¼šç ´è¯‘è‚¿ç˜¤è½¬ç§»æ–°è·¯å¾„**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡äºº
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€cancer
- ğŸ“ **æè¿°**ï¼šå¾ªç¯è‚¿ç˜¤ç»†èƒï¼ˆCTCsï¼‰ä½œä¸ºç™Œç—‡è½¬ç§»çš„"ç§å­"ï¼Œå…¶æ•è·æŠ€æœ¯ä¸ç”Ÿç‰©å­¦è§£æå¯¹çªç ´æ™šæœŸæ²»ç–—ç“¶é¢ˆã€å¼€å‘ç²¾å‡†å¹²é¢„ç­–ç•¥å…·æœ‰
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248522&idx=3&sn=dc75917e2830f925b22a7f9e3e0469bd)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 50 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-å…¬ä¼—å·)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (47æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE300217 åˆ©ç”¨ä¸¤ç§æ–°å‹æ¶²æ»´å¼å•ç»†èƒRNAæµ‹åºå¹³å°ï¼šä¸10x Genomicsçš„æ¯”è¾ƒç ”ç©¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šsequencingã€single-cellã€10xã€genomics
- ğŸ“ **æè¿°**ï¼šContributors : Alesia Maluchenko ; Ekaterina Avsievich ; Iaroslava Zvorygina ; Zoia Antysheva ; Denis Maksimov ; Margarita Boytsova ; Dmitry Tabakov ; Natalia Bodunova ; Olga Glazova ; Dmitry Tychinin ; Alexander Bolbat ; Ekaterina Petriaikina ; Dmitry Svetlichnyy ; Sergey Yudin ; Anton Keskinov ; Vladimir Yudin ; Mary Woroncow ; Veronika Skvortsova ; Julia Krupinova ; Pavel VolchkovSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusHere we performed a comparison of two droplet-based high-throughput single-cell platforms, namely, SeekOne and MobiDrop with a widely-used commercial platform from 10x Genomics. The use of different types of samples allowed us to evaluate the performance of the platforms on cell suspensions of varying complexity and quality. 10x showed generally superior performance, although all platforms compared in this study showed acceptable gene yield and allowed identification of all expected cell types. Taking into account the cost and availability of devices and reagents required for each platform and the flexibility in the number of samples loaded onto the chip, SeekOne and MobiDrop might serve as a good alternative. The results of the current comparison will support the community's efforts to compare different aspects, including sample amount requirements, throughput, cell quality, gene capture efficiency and cell type representativeness.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300217)

**2.** â­ **GSE310026 å†…åœ¨ RB æ¿€æ´»è¯±å¯¼è‚¿ç˜¤å’ŒåŸºè´¨æŠ—è‚¿ç˜¤ååº”ï¼Œä»è€Œé™åˆ¶ä¸‰é˜´æ€§ä¹³è…ºç™Œ [scRNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€scRNA
- ğŸ“ **æè¿°**ï¼šContributors : Yin Wan ; Jianxin Wang ; Thomas N Oâ€™Connor ; Vishnu Kumarasamy ; Ioannis Sanidas ; Scott I Abrams ; Agnieszka K Witkiewicz ; Erik S KnudsenSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe RB tumor suppressor is a key regulator of cell cycle progression that is often inactivated in triple-negative breast cancer (TNBC). Recent studies indicate that drugs activating RB have multiple tumor-suppressing effects on the tumor and the tumor microenvironment (TME). Here, we utilize a constitutively active RB protein incapable of being phosphorylated and inactivated by CDKs (RBÎ”CDK) to assess the intrinsic sufficiency of RB activation on tumor suppression. Expression of RBÎ”CDK in TNBC cell lines uniformly inhibited proliferation. Transcriptomic analysis revealed suppression of cell cycle genes and the induction of genes associated with interferon response. Similarly, tumor growth and metastasis were suppressed in RBÎ”CDK expressing human xenograft and mouse syngeneic tumor models. RB activation was sufficient to dramatically alter the TME, wherein tumor growth suppression was mediated by CD8+ T cells. Together, these data indicate that active RB suppresses TNBC progression in cancer cell-autonomous and non-autonomous mechanisms.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310026)

**3.** â­ **GSE310025 å†…åœ¨ RB æ¿€æ´»è¯±å¯¼è‚¿ç˜¤å’ŒåŸºè´¨æŠ—è‚¿ç˜¤ååº”ï¼Œä»è€Œé™åˆ¶ä¸‰é˜´æ€§ä¹³è…ºç™Œ [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Yin Wan ; Jianxin Wang ; Thomas N Oâ€™Connor ; Vishnu Kumarasamy ; Ioannis Sanidas ; Scott I Abrams ; Agnieszka K Witkiewicz ; Erik S KnudsenSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusThe RB tumor suppressor is a key regulator of cell cycle progression that is often inactivated in triple-negative breast cancer (TNBC). Recent studies indicate that drugs activating RB have multiple tumor-suppressing effects on the tumor and the tumor microenvironment (TME). Here, we utilize a constitutively active RB protein incapable of being phosphorylated and inactivated by CDKs (RBÎ”CDK) to assess the intrinsic sufficiency of RB activation on tumor suppression. Expression of RBÎ”CDK in TNBC cell lines uniformly inhibited proliferation. Transcriptomic analysis revealed suppression of cell cycle genes and the induction of genes associated with interferon response. Similarly, tumor growth and metastasis were suppressed in RBÎ”CDK expressing human xenograft and mouse syngeneic tumor models. RB activation was sufficient to dramatically alter the TME, wherein tumor growth suppression was mediated by CD8+ T cells. Together, these data indicate that active RB suppresses TNBC progression in cancer cell-autonomous and non-autonomous mechanisms.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310025)

**4.** â­ **GSE309813 Deoxyguanosine Kinase Deficiency Couples Purine Metabolism to Innate Immune Activation and Lipid Accumulation in Hepatocytes**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€metabolismã€kinase
- ğŸ“ **æè¿°**ï¼šContributors : Maija Corey ; Sonia Sharma ; Jeamin JungSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMitochondrial DNA depletion syndromes (MDS) encompass a heterogeneous set of metabolic disorders caused by defects in enzymes responsible for maintaining mitochondrial nucleotide pools and genome integrity. Among these, deoxyguanosine kinase (DGUOK) acts within the mitochondrial purine-salvage pathway and loss-of-function mutations give rise to DGUOK deficiency, a severe hepatocerebral form of MDS marked by liver failure, neurodevelopmental impairment, and systemic metabolic inflammation. Although the clinical manifestations of DGUOK deficiency have been primarily ascribed to defective mitochondrial DNA (mtDNA) replication, some patients exhibit hepatic steatosis and inflammation despite preserved mtDNA content, suggesting that DGUOK deficiency may deregulate additional metabolic and immune pathways. Here we show that DGUOK depletion reprograms hepatocellular metabolism and innate immune signaling through a purine-dependent mechanism operating independently of mtDNA depletion. In Human hepatocellular carcinoma (HEPG2) hepatocytes subjected to siRNA-mediated DGUOK silencing, mitochondrial architecture and respiration remained intact but cells exhibited pronounced lipid droplet accumulation and a robust cell-intrinsic innate immune type I interferon response. Bulk RNA sequencing revealed widespread transcriptional reprogramming, including upregulation of human endogenous retroviruses (HERVs) and interferon-stimulated genes (ISGs), suppression of lipid metabolic pathways, and changes in purine, methionine, and methylation-associated gene networks. Perturbing purine homeostasis through deoxyadenosine (dAdo) supplementation in wild-type cells phenocopied DGUOK disruption, causing cellular DNA hypomethylation and activation of viral mimicry pathways. Together, these findings identify DGUOK as a central regulator of the purine-regulated lipid-immune axis in hepatocytes, demonstrating that mitochondrial nucleotide salvage preserves hepatic immune and metabolic homeostasis beyond its canonical role in mtDNA synthesis. By linking purine imbalances to steatosis and type I interferon activation, this study establishes a mechanistic framework for immunometabolic pathology in DGUOK deficiency.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309813)

**5.** â­ **GSE238130 Single-cell genomics highlight MYC-upregulation, metabolic activation, and altered cell interactions in T-PLL progression**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šmetabolicã€single-cellã€genomics
- ğŸ“ **æè¿°**ï¼šContributors : Linus Wahnschaffe ; Marco Herling ; Tea Pemovska ; Philipp B Staber ; Marek Franitza ; Theodore Georgomanolis ; Kerstin BeckerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensT-prolymphocytic leukemia (T-PLL) is a rare T-cell malignancy usually associated with rapid tumor progression already at first diagnosis. A small subset of 15-25% of T-PLL patients, however, presents at a primarily indolent disease stage. These patients feature asymptomatic lymphocytosis with stable tumor load over several months to years, before inevitably progressing into active-stage T-PLL. In this study, we employed single-cell RNA sequencing of longitudinally acquired samples to investigate the pathobiologic mechanism underlying this transition from indolent to active T-PLL. We detected consistent deregulations of relevant cancer-associated pathways, centered around a strong upregulation of MYC target gene signatures that highly correlated with an enhanced energy metabolism in active-stage T-PLL cells. Both in silico and ex vivo analyses identified a marked restriction of cell energy metabolism during the indolent disease stage that strongly confined the outgrowth of T-PLL cells. Active T-PLL cells were capable to surpass this metabolic restriction. Analyses of immune-signaling pathways of T-PLL cells as well as the tumor microenvironment further revealed a progressive detachment from immune-related survival signals and escape from the homeostatic control. In summary, we identified both global alterations of gene expression patterns as well as patient-specific lesions that enabled the transformation into active-stage T-PLL. This study provides the first single-cell-resolved genomic analysis of T-PLL, providing valuable and novel insights into the intra-tumor heterogeneity of T-PLL, mechanisms of tumor evolution, as well as its interaction with the tumor microenvironment.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE238130)

**6.** **GSE310176 æœè‡ OSC åŸºå› ç»„ï¼šè½¬åº§å­å’Œ piRNA ç”Ÿç‰©å­¦ç ”ç©¶èµ„æº [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seqã€genome
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Drosophila melanogasterAccurate genome assemblies are critical for understanding small RNA-mediated genome defense. In animals, the PIWI-interacting RNA (piRNA) pathway protects genome integrity by silencing transposable elements. Studying how piRNAs are generated and how they guide heterochromatin formation requires complete reconstruction of genomic piRNA source loci and detailed transposon maps. Here, we present a high-quality de novo genome assembly of Drosophila melanogaster ovarian somatic cells (OSCs), a widely used cell line that recapitulates nuclear piRNA biology. The OSC genome differs substantially from the reference genome, with major differences in transposon content and piRNA cluster composition. Our assembly resolves the 700 kb flamenco locus, the primary piRNA cluster in OSCs, and provides a genome-wide transposon map. Using this resource, we characterize piRNA source loci, reveal how piRNA cluster composition determines transposon-derived piRNA profiles, and clarify the widespread impact of the nuclear piRNA pathway on heterochromatin. Finally, we provide an open platform for integrating user-generated datasets with the OSC genome, creating a community resource for studying transposon control and piRNA biology.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310176)

**7.** **GSE250428 NAT10 é€šè¿‡æŸ“è‰²è´¨ç›¸å…³ tRNA è°ƒèŠ‚ p300/CBP æ´»æ€§æ¥ä¿ƒè¿›ç™Œç—‡è½¬ç§» [ChIP-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€ChIP-seq
- ğŸ“ **æè¿°**ï¼šContributors : Ruhul Amin ; Ngoc-Han Ha ; Tinghu Qiu ; Ronald Holewinski ; Huaitian Liu ; Andy D Tran ; Maxwell P Lee ; Supuni T Gamage ; Thorkell Andresson ; Jordon L Meier ; Kent W HunterSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusAcetylation of proteins and RNA is crucial for development and cancer progression. NAT10 is the sole RNA acetylase responsible for N4-acetylcytidine (ac4C) modification of various RNAs. Our study reveals that NAT10 loss significantly reduces lung metastasis in breast cancer mouse models. NAT10 interacts with a mechanosensitive, metastasis-susceptibility protein complex at the nuclear pore. Mechanistically, NAT10-mediated acetylation of chromatin-associated tRNAs enhances p300/CBP activity. Without NAT10, acetylation of these tRNAs decreases, leading to p300/CBP inactivation and mislocalization. As a result, NAT10 depletion disrupts enhancer organization, altering gene transcription critical for metastasis, including reduced chemokines that recruit myeloid cells and create a less metastasis-prone tumor microenvironment. Our findings highlight the distinct role of NAT10 in acetylated tRNA-dependent regulation of enhancer function in metastatic tumor cells and its impact on tumor-immune interactions influencing metastasis.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250428)

**8.** **GSE250284 NAT10 é€šè¿‡æŸ“è‰²è´¨ç›¸å…³ tRNA è°ƒèŠ‚ p300/CBP æ´»æ€§æ¥ä¿ƒè¿›ç™Œç—‡è½¬ç§» [RNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€RNA-seq
- ğŸ“ **æè¿°**ï¼šContributors : Ruhul Amin ; Ngoc-Han Ha ; Tinghu Qiu ; Ronald Holewinski ; Huaitian Liu ; Andy D Tran ; Maxwell P Lee ; Supuni T Gamage ; Thorkell Andresson ; Jordon L Meier ; Kent W HunterSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusAcetylation of proteins and RNA is crucial for development and cancer progression. NAT10 is the sole RNA acetylase responsible for N4-acetylcytidine (ac4C) modification of various RNAs. Our study reveals that NAT10 loss significantly reduces lung metastasis in breast cancer mouse models. NAT10 interacts with a mechanosensitive, metastasis-susceptibility protein complex at the nuclear pore. Mechanistically, NAT10-mediated acetylation of chromatin-associated tRNAs enhances p300/CBP activity. Without NAT10, acetylation of these tRNAs decreases, leading to p300/CBP inactivation and mislocalization. As a result, NAT10 depletion disrupts enhancer organization, altering gene transcription critical for metastasis, including reduced chemokines that recruit myeloid cells and create a less metastasis-prone tumor microenvironment. Our findings highlight the distinct role of NAT10 in acetylated tRNA-dependent regulation of enhancer function in metastatic tumor cells and its impact on tumor-immune interactions influencing metastasis.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250284)

**9.** **GSE310215 FFPE å’Œå†·å†»ç»“ç›´è‚ ç™Œç»„ç»‡çš„ç©ºé—´è½¬å½•ç»„åˆ†æ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€spatial
- ğŸ“ **æè¿°**ï¼šContributors : Kullanist Thanormjit ; Thanawat Suwatthanarak ; Vitoon Chinswangwatanakul ; Pariyada TanjakSeries Type : OtherOrganism : Homo sapiensThis dataset contains spatial whole-transcriptome profiles from colorectal cancer (CRC) tissues preserved using formalin-fixed paraffin-embedded (FFPE), fresh frozen (FF), and snap frozen (SF) methods. Samples were obtained from a patient with stage IV CRC during surgical resection at Siriraj Hospital, Mahidol University, Thailand. Each tissue type was sectioned, stained for Pan-cytokeratin (PanCK), CD45, and SYTO13, and analyzed using the NanoString GeoMx Digital Spatial Profiler with the Human Whole Transcriptome Atlas panel. A total of 36 areas of illumination (AOIs) representing epithelial (PanCKâº), immune (CD45âº), and stromal (PanCKâ»/CD45â») compartments were collected. Sequencing was performed on an Illumina NovaSeq 6000 platform, and raw counts were processed using NanoString DSP Analysis Suite v3.1 and R for normalization and quality control. This dataset provides spatially resolved gene-expression information across different preservation conditions of CRC tissues to support comparative analysis and method evaluation in spatial transcriptomics.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310215)

**10.** **GSE309815 Single-cell RNA-seq of undirected human cerebral organoids (HuCOs) infected with MV1 or MV2 compared with uninfected controls at 120 and 180 days post-infection**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seqã€single-cell
- ğŸ“ **æè¿°**ï¼šContributors : Catheryn Haigh ; Bradley Groveman ; James Carroll ; Craig Martens ; Justin Lacks ; Amirhossein Shamsaddini ; Paul GardinaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensUndirected human cerebral organoids (HuCOs) derived from induced pluripotent stem cells (hiPSCs) were used to model neural development and infection response in vitro. Organoids were maintained in spinning bioreactors and divided into three experimental groups: MV1-infected, MV2-infected, and uninfected control (NBH). Each infection group was harvested at two developmental stages, approximately 120 and 180 days post-infection (dpi), following five months of infection. Single-cell RNA-seq libraries were prepared using the 10x Genomics Chromium Next GEM Single Cell 3â€² Reagent Kits v3.1 and sequenced on an Illumina NovaSeq 6000 platform. The study aimed to characterize infection-induced transcriptional and cellular changes across time points and between infection subtypes. This dataset provides a high-resolution single-cell transcriptomic resource to explore cellular heterogeneity and hostâ€“pathogen interactions in undirected human cerebral organoids.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309815)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 37 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰

**1.** **Foli-seqâ€”â€”ç²ªä¾¿è„±è½ç»„æµ‹åºâ€”â€”å¯æ•æ‰å¥åº·å’Œç‚ç—‡è‚ é“çš„å…ç–«åŠ¨æ€**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šimmuneã€sequencing
- ğŸ“ **æè¿°**ï¼šFoli-seq uses fecal human cells to reveal gut and immune activity, expanding RNA sequencing to noninvasive monitoring of intestinal health and inflammation...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/foli-seq-fecal-exfoliome-sequencing-captures-immune-dynamics-of-the-healthy-and-inflamed-gut/)

**2.** **CRISPRæŠ€æœ¯ä¸ºæ”»å…‹è€è¯æ€§è‚ºç™Œå¼€è¾Ÿæ–°é€”å¾„**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancer
- ğŸ“ **æè¿°**ï¼šScientists used CRISPR to disable the NRF2 gene, restoring chemotherapy sensitivity in lung cancer cells and slowing tumor growth. The technique worked even when only a fraction of tumor cells were edited, making it practical for real-world treatment. Since NRF2 fuels resistance in several cancers, the approach could have broad impact.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.sciencedaily.com/releases/2025/11/251117095637.htm)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| RNA-seq | 14 |
| ä»£è°¢ | 11 |
| å…ç–« | 11 |
| ç™Œç—‡ | 11 |
| cancer | 11 |
| å•ç»†èƒ | 9 |
| ç”Ÿä¿¡ | 7 |
| genomics | 7 |
| è‚¿ç˜¤ | 6 |
| ChIP-seq | 6 |
| genome | 5 |
| ç¥ç» | 4 |
| è€è¯ | 3 |
| sequencing | 3 |
| metabolic | 3 |
| single-cell | 3 |
| ATAC-seq | 3 |
| metabolism | 3 |
| è›‹ç™½è´¨ç»„ | 3 |
| å¿ƒè„ | 3 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (50æ¡)</summary>

<div class="details-content" markdown="1">

- [Scienceé‡ç£…â€”â€”é¦–ä¸ªå¤§è§„æ¨¡äººç±»é€ è¡€å•ç»†èƒè›‹ç™½è´¨ç»„å›¾è°±é—®ä¸–](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248522&idx=2&sn=e682573eb4c26336de4443f5dbc2c6b9)
- [Natureå­åˆŠï¼šåäººå­¦è€…å‘ç°ç™Œç—‡å…ç–«æ²»ç–—æ–°é¶ç‚¹â€”â€”TRAP1](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247788981&idx=3&sn=7785e3c190c3356672969671234addc5)
- [Natureå­åˆŠï¼šæ¨å‹‡/ç‹æ–‡å¹¿å›¢é˜Ÿç­‰å¼€å‘é€šç”¨å‹ç™Œç—‡ç–«è‹—ï¼Œåˆ©ç”¨ä¹™è‚ç—…æ¯’è¡¨é¢æŠ—åŸï¼Œæ¸…é™¤å®ä½“ç˜¤](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247790102&idx=2&sn=245a4dd5ced64cc0d5174dc4d422f935)
- [å…‰æ§ä»£è°¢é‡ç¼–ç¨‹ï¼Nano-PROTACå¦‚ä½•ç‚¹ç‡ƒç„¦äº¡å…ç–«æ–°æˆ˜åœºï¼Ÿ](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247486998&idx=1&sn=6f59cdc1e39555e96aae0449888b3dd6)
- [é…¸æ€§å¾®ç¯å¢ƒçš„â€œç»Ÿæ²»æœ¯â€ï¼šè‚¿ç˜¤å¦‚ä½•åœ¨æ¶åŠ£ä»£è°¢å‹åŠ›ä¸‹å®Œæˆèƒ½é‡å†ç¼–ç¨‹ï¼Ÿ](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247487051&idx=1&sn=439be4bf0dae0c5cf7af417367352ac0)
- [ä»DNAä¿®å¤åˆ°å…ç–«æ¿€æ´»ï¼šç´«è‰ç´ çº³ç±³è¯çš„æ–°å‹æŠ—è‚¿ç˜¤æœºåˆ¶](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247487107&idx=1&sn=a3bb0ef120817d571f0dadb351e2846d)
- [èƒ½é‡é€†è½¬è¡°è€ï¼šçº³ç±³è¯ç‰©å¦‚ä½•ç»´æŒçº¿ç²’ä½“ç¨³æ€ã€é‡å¡‘ç»†èƒä»£è°¢ï¼Ÿ](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247487166&idx=1&sn=856d6161fbead717c37fd3e7b862b919)
- [ç ´è¯‘TMAOä»£è°¢è½´ï¼å…­å‘³åœ°é»„æ–¹è”åˆç›Šç”ŸèŒå¦‚ä½•æˆä¸ºå¿ƒè¡€ç®¡ä¿æŠ¤æ–°ç­–ç•¥ï¼Ÿ](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247487326&idx=1&sn=904973cb0da653788054134b268f8b51)
- [CellWhispererè®©èŠå¤©å¼åˆ†ææˆä¸ºç°å®ï¼›è‚¿ç˜¤äºšå…‹éš†è¿›åŒ–åˆ†ææ–°å·¥å…·ï¼›äººç±»çš®è‚¤æ·‹å·´ç®¡â€œæ–°åœ°å›¾â€ï¼›æ–°ç­–ç•¥è§£æBç»†èƒå¤šæ ·æ€§ ç­‰](https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&mid=2247533696&idx=1&sn=abeb6812d567829a596ed887f7d20fdd)
- [è¯¦è§£ï¼šé…’ç²¾ï¼ˆä¹™é†‡ï¼‰ä»£è°¢è¿‡ç¨‹](https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&mid=2247484058&idx=1&sn=a0c8a663763b840909163b2cfba7da33)
- [æœåŠ¡å™¨è½»æ¾ä¸Šæ‰‹ï¼é¢„è£…åƒæ¬¾è½¯ä»¶+æŠ€æœ¯è€å¸ˆä¸€å¯¹ä¸€æŒ‡å¯¼ï¼Œç”Ÿä¿¡åˆ†æä»æœªå¦‚æ­¤ç®€å•](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498504&idx=2&sn=451756cda47d1298a1db01a42a21d6b0)
- [ä¿å§†å¼æ•™å­¦â€”â€”ä»å·®å¼‚åˆ†æåˆ°GESAå¯Œé›†åˆ†æ](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498504&idx=1&sn=595795842aa3d36fc8be492b2a28cadc)
- [Cell |çœ‹çœ‹è¿™å•ç»†èƒåˆ†æçš„ï¼Œè§£å†³ç—…æ¯’æ„ŸæŸ“çš„ç»†èƒå¼‚è´¨æ€§ç°è±¡ï¼Œä¸ºå•¥åŒä¸€ç±»ç»†èƒï¼Œåªæœ‰è¿™ç§äºšå‹æ˜“æ„Ÿ](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495601&idx=1&sn=7e1946e4d7ab0f19dd6eaa93d73e38ae)
- [æœ€æ–°10+çº¯ç”Ÿä¿¡ï¼Œç©ºè½¬Visium+COSMxå®šä¹‰æ²»ç–—ååº”ç›¸å…³çš„nicheï¼ç”Ÿä¿¡åˆ†ææ–°æ€è·¯ï¼Œå€¼å¾—æ”¶è—å­¦ä¹ ï¼](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503973&idx=1&sn=933c578b1468cc5cd971dca0c86b2b41)
- [ã€Šç™Œç»†èƒã€‹ï¼šå¥½ä¸€æ‹›é‡‘è‰è„±å£³ï¼ä¸­å±±å¤§å­¦å›¢é˜Ÿå‘ç°è‚ ç™Œå¯¹KRASå’ŒEGFRåŒé‡é¶å‘æ²»ç–—äº§ç”Ÿè€è¯æ€§çš„æ–°æœºåˆ¶](https://mp.weixin.qq.com/s?__biz=MzI4ODc5MDI5NA==&mid=2247503509&idx=1&sn=8942c5430d3ac4bd91287e9f58ce2943)
- [å‘Šåˆ«â€œæ€æ•Œä¸€åƒè‡ªæŸå…«ç™¾â€ï¼ŒåŒé¶ç‚¹æŠ‘åˆ¶å‰‚ä»æºå¤´ç²¾å‡†ç‹™å‡»è‡ªèº«å…ç–«ç–¾ç—…](https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&mid=2247568946&idx=2&sn=ea2efb0cbfc7fa7fd5e42fd67c8a0026)
- [â€œå‘ç°å°±æ˜¯æ™šæœŸâ€çš„è‡´å‘½ç™Œç—‡ä¸å†æ— è§£ï¼åˆ›æ–°ç–—æ³•è®©ç”Ÿå­˜ç‡æ¥è¿‘ç¿»å€](https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&mid=2247568946&idx=1&sn=0138c59ba51cc038087be488b5892d66)
- [Nat Commun|å…¶å®å•ç»†èƒå’Œç©ºè½¬çš„è”åˆæ€è·¯å¯ä»¥åè½¬ä¸€ä¸‹ï¼Œä»Šå¤©æˆ‘ä»¬å­¦ä¹ ä¸€ä¸‹å¦‚ä½•ç”¨ç©ºé—´æ•°æ®â€œåå‘æ³¨é‡Šâ€å•ç»†èƒæ•°æ®ï¼Œæ€è·¯æ‰“å¼€ï¼](https://mp.weixin.qq.com/s?__biz=Mzg2NDcxMzYwNg==&mid=2247490849&idx=1&sn=a344ef930b20f30bfc25d0bb161f2013)
- [ç”Ÿä¿¡å…¥é—¨&æ•°æ®æŒ–æ˜çº¿ä¸Šç›´æ’­è¯¾12æœˆç­](https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&mid=2247547012&idx=1&sn=f55923d9a6d9e04c3e923c2a3cae6e56)
- [æ–‡çŒ®åˆ†äº«|Gut Microbesï¼šå•ç»†èƒå°ºåº¦è§£æå…‹ç½—æ©ç—…ï¼šè‚ é“å¾®ç”Ÿç‰©ç»„çš„â€œç–¾ç—…æŒ‡çº¹â€ä¸â€œç–—æ•ˆå¯†ç â€](https://mp.weixin.qq.com/s?__biz=MzkxMDY1MjU1OA==&mid=2247488544&idx=1&sn=e668b1064411a6ceac958bcbb7123898)
- [Science | Hao Zhuå›¢é˜Ÿæ­ç¤ºè‚è„ä»£è°¢åˆ†åŒºå†³å®šè‚ç™Œèµ·æºçš„æœºåˆ¶](https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&mid=2247507346&idx=2&sn=24dfe2c9892370f3db6a1eb5dc382be0)
- [Nat Communä¸¨å›½å®¶è›‹ç™½è´¨ç§‘å­¦ä¸­å¿ƒï¼ˆåŒ—äº¬ï¼‰å”ä¸½å›¢é˜Ÿåˆä½œå‘ç°å·¨å™¬ç»†èƒå¤„ç†è„‚è›‹ç™½å¤±è°ƒä¿ƒè¿›è„‚è´¨ä»£è°¢ç´Šä¹±ç›¸å…³ç–¾ç—…çš„å‘å±•](https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&mid=2247507348&idx=1&sn=5f3ef341238cabe5499a2a5ebab6a739)
- [Cellå†æ·»æŠ—ç™Œæ–°æ˜Ÿï¼ŒAOAHæ”¹å†™ç™Œç—‡æ²»ç–—è§„åˆ™ï¼](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248522&idx=7&sn=21cc941eb614449efd06d9a2d23b6514)
- [ç™»é¡¶topçº§æœŸåˆŠï¼GWAS+å•ç»†èƒåˆ†æè§£å¯†ç–¾ç—…æœºåˆ¶ï¼Œè¿™æ³¢æ€è·¯å¿…é¡»å­¦ï¼](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248522&idx=6&sn=3013bdf2c0e07f0bd5f5dac7287471db)
- [ä¸­å›½åŒ»å­¦ç§‘å­¦é™¢æ—ä¸œæ˜•é™¢å£«ç­‰å›¢é˜Ÿ50+çªç ´ï¼ç»å…¸é€šè·¯é¦–æ¬¡è§£é”é£Ÿç®¡é³ç™Œå‘½é—¨ï¼](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248522&idx=5&sn=32264c64743937888f4885b2d24357f7)
- [67åˆ†å·¨ä½œï¼Œå¸¦ä½ ç”¨çˆ†ç«çš„ä»£è°¢é‡ç¼–ç¨‹å®ç°å¼¯é“è¶…è½¦](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248586&idx=7&sn=2f0e47bc4d59b2cdb8843f8239717721)
- [Cell Genomæœ€æ–°åŠ›ä½œï¼å¤šç»„å­¦+å­Ÿå¾·å°”éšæœºåŒ–åˆ†æï¼Œç ´è§£è¡€æ¸…ä»£è°¢ç‰©ä¸æ…¢æ€§ç–¾ç—…çš„é—ä¼ å…³è”ï¼](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248586&idx=6&sn=2bc11d701dce9dc5c40c0d9bebe09084)
- [28 æ ·æœ¬ IF40.4ï¼è§£å¯†ç‹çº¢é˜³é™¢å£«å›¢é˜Ÿçš„å•ç»†èƒåˆ›æ–°å¯†ç ](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248586&idx=5&sn=f36e95546c3b618a9db2425c6f17d333)
- [æœ€æ–°27+ç”Ÿä¿¡ï¼ŒåŸæ¥åªåšäº†è¿™äº›æ“ä½œï¼](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248586&idx=4&sn=0a2302846b821f2c24b5778d089542b9)
- [å¤æ—¦å¤§å­¦10å•ç»†èƒ+6ç©ºè½¬ï¼Œç»“åˆå…¬å¼€æ•°æ®ï¼Œç™»ä¸€åŒºé¡¶åˆŠ](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248586&idx=2&sn=c589221a923eb6e87555bcb0b48a85b1)
- [Scienceæ­ç§˜å…ç–«ç»†èƒçš„â€œå‡è„‚å¤©èµ‹â€ï¼šTç»†èƒé€šè¿‡èƒ†å›ºé†‡è½¬è¿ï¼Œæ‚„æ‚„æŠ‘åˆ¶è„‚è‚ªå¸æ”¶](https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&mid=2651248586&idx=1&sn=66c56773d3c751794de87f6a59650038)
- [ç³»ç»Ÿæ€§è¯„ä»·ï¼šé£Ÿç®¡é™è„‰æ›²å¼ æ‚£è€…èƒ½å¦å®‰å…¨æœ‰æ•ˆçš„è¿›è¡Œé£Ÿç®¡è‚¿ç˜¤çš„å†…é•œåˆ‡é™¤æœ¯ï¼Ÿ](https://mp.weixin.qq.com/s?__biz=MzkyODQzODM1OQ==&mid=2247485563&idx=1&sn=964882f40e24427079d7316bf97aef8f)
- [Natureé‡ç£…ï¼šé²¸é±¼é•¿å¯¿ä¸”ä¸æ‚£ç™Œç—‡ï¼Œå…³é”®åœ¨äºè¿™ä¸ªDNAä¿®å¤è›‹ç™½ï¼Œæˆ–å¯å¸®åŠ©äººç±»å»¶é•¿å¯¿å‘½](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247788727&idx=1&sn=738d8f41cb15eedbfdfcf1089c2ab6af)
- [Natureå­åˆŠï¼šæˆ‘å›½å­¦è€…è¯å®ï¼Œè¿åŠ¨å¯¹å¥³æ€§å¿ƒè„å¥åº·çš„å¸®åŠ©æ›´å¤§](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247788925&idx=3&sn=00a58b4ddc419bc08da0d77e48fc3236)
- [Nature Agingï¼šç‹å®æ—å›¢é˜Ÿå‘ç°é˜¿å°”èŒ¨æµ·é»˜ç—…æ²»ç–—æ–°é¶ç‚¹ï¼Œå¹¶æ‰¾åˆ°æ½œåœ¨è¯ç‰©](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247788925&idx=2&sn=e45eb118e3c78aafd628bc5a3f4d4922)
- [STTTï¼šéƒ‘å·å¤§å­¦Ã—å¤æ—¦å¤§å­¦å¼€å‘å…‰é—ä¼ å­¦ç–—æ³•ï¼Œæ²»ç–—é’å…‰çœ¼ç­‰è§†ç½‘è†œç¥ç»é€€è¡Œæ€§ç—…å˜](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247788981&idx=2&sn=be250aa363070712661063bca973022b)
- [CNSè®ºæ–‡å•ç»†èƒæ—¶ç©ºç»„å­¦ä¸æœºå™¨å­¦ä¹ è¯¾é¢˜æ€è·¯è®¾è®¡](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789041&idx=2&sn=5d797f15f3362538795dab0b781629b1)
- [Cellå­åˆŠï¼šæµ™æ±Ÿå¤§å­¦å­”å¨œå›¢é˜Ÿå¼€å‘â€œä»¥ç™Œæ²»ç™Œâ€ç­–ç•¥ï¼Œé˜²æ­¢ç™Œç—‡å¤å‘](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789257&idx=2&sn=fa2b3daacf8dff1e8f7f76987c773702)
- [è¯ºå¥–å›¢é˜Ÿè¿›å†›in vivo CAR-Tï¼Œåˆ©ç”¨æ–°å‹åŒ…è†œé€’é€è½½ä½“ï¼Œåœ¨ä½“å†…ç›´æ¥ç”ŸæˆCAR-Tç»†èƒ](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789318&idx=2&sn=43c57e1e40c5003d37a66f67eed7f244)
- [é“æ­»äº¡æŠ—ç™Œæ–°çªç ´ï¼èƒŒé èƒŒä¸¤ç¯‡Natureï¼šé¶å‘FSP1ï¼Œä¿ƒè¿›ç™Œç—‡é“æ­»äº¡](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789318&idx=1&sn=8fa988d55c58767b04808c82e15c4a1f)
- [Cell Stem Cellï¼šæ›¾å®‰/å‘¨å¿—åˆšåˆä½œå‘ç°å¹¼å¹´å¿ƒè„å†ç”Ÿå…³é”®ç»†èƒï¼Œä¸ºé‡å¯æˆå¹´å¿ƒè„å†ç”Ÿæä¾›å…¨æ–°é¶ç‚¹](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789482&idx=2&sn=0cc3170448b444a20641e8d52ab4adaa)
- [ä¸œå—å¤§å­¦Ã—å—äº¬å¤§å­¦åˆä½œCellå­åˆŠï¼šåˆ©ç”¨ç»†èƒå¤–å›Šæ³¡è›‹ç™½è´¨ç»„å’Œè„‚è´¨ç»„ï¼Œæ—©æœŸè¯Šæ–­å¸•é‡‘æ£®ç—…](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789550&idx=3&sn=c00c717c0f9fc241e3c335e03a0c167c)
- [è¶…è¶ŠCRISPRï¼šåŸºäºADARçš„RNAç¼–è¾‘æŠ€æœ¯ï¼Œæ­£åœ¨é‡å¡‘ç™Œç—‡ç­‰ç–¾ç—…çš„æ²»ç–—](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789550&idx=1&sn=911ce8a3134fb679a2c138af1976b611)
- [Nature Agingï¼šå­¦ä¸€é—¨å¤–è¯­ï¼Œè®©å¤§è„‘æ›´å¹´è½»](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789725&idx=2&sn=8209adb1280ccc35df20f1c86722a043)
- [Cellå­åˆŠï¼šåäººå­¦è€…è¯å®ï¼Œæ¯äº²ç³–å°¿ç—…ï¼Œå„¿å­æ˜“æ‚£å¿ƒè¡€ç®¡ç–¾ç—…ï¼Œå¥³å„¿åˆ™ä¸å—å½±å“](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789851&idx=3&sn=380430d44e26010f98d3340cf0852b96)
- [å—äº¬åŒ»ç§‘å¤§å­¦èƒ¡å¿—æ–Œå›¢é˜Ÿå‘ç°ï¼Œæ¯äº²å­•æœŸç¼ºä¹èƒ†å›ºé†‡ï¼Œåä»£å…ˆå¤©æ€§å¿ƒè„ç—…é£é™©å‡é«˜](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789902&idx=2&sn=0b7ea4a5f1dc2076677e52f144b97c5f)
- [å¤©æ´¥åŒ»ç§‘å¤§å­¦æœ€æ–°Scienceè®ºæ–‡ï¼šæ–½ç¦ä¸œå‘ç°å›¢é˜ŸæŠ‘åˆ¶å¤§è„‘ç‚ç—‡åŠç¥ç»é€€è¡Œçš„æ–°é¶ç‚¹ï¼Œå¼€è¾Ÿç¥ç»ç–¾ç—…æ²»ç–—æ–°è·¯å¾„](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789902&idx=1&sn=3032b9e75d25aaf120559aeeb69fef13)
- [è¶…è¶Šé’è’¿ç´ ï¼Œå…‹æœè€è¯æ€§ï¼é¦–ä¸ªéé’è’¿ç´ æŠ—ç–Ÿç–¾è¯ç‰©å³å°†ä¸Šå¸‚](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789962&idx=2&sn=53fa42aa2737c757266e30030c594200)
- [Natureè¿å‘4ç¯‡è®ºæ–‡ï¼Œæ­å¼€è¿™ç§RNAç¼–è¾‘é…¶åœ¨è‡ªèº«å…ç–«ç–¾ç—…ä¸­çš„ä½œç”¨](https://mp.weixin.qq.com/s?__biz=MzU1MzMxMzcyMg==&mid=2247789962&idx=1&sn=28445745bbaa848b3c3f8cae66df6f0e)
- [ä»£è°¢è°ƒæ§æ–°é¶ç‚¹ï¼ã€ŠPhytomedicineã€‹æ­ç¤ºHSYAæ”¹å–„å¿ƒè‚ŒæŸä¼¤çš„å…¨æ–°æœºåˆ¶](https://mp.weixin.qq.com/s?__biz=Mzk3NTY2NDk1Nw==&mid=2247487268&idx=1&sn=4a2658dd5292bcd880b3b2240c30164c)

</div>

</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (37æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE282705 BLU-222, a Potent CDK2 Inhibitor, Synergizes with CDK4/6 Inhibitors to Overcome Drug Resistance in HRâ€“Positive and Triple-Negative Breast Cancer by Inducing p21 and p27](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282705)
- [GSE267549 A functional genomics atlas enhanced by convolutional neural networks facilitates clinical interpretation of disease relevant variants in non-coding regulatory elements [wt RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE267549)
- [GSE263338 A functional genomics atlas enhanced by convolutional neural networks facilitates clinical interpretation of disease relevant variants in non-coding regulatory elements [ATAC-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263338)
- [GSE263337 A functional genomics atlas enhanced by convolutional neural networks facilitates clinical interpretation of disease relevant variants in non-coding regulatory elements [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263337)
- [GSE263336 A functional genomics atlas enhanced by convolutional neural networks facilitates clinical interpretation of disease relevant variants in non-coding regulatory elements [plasmid DNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263336)
- [GSE263335 A functional genomics atlas enhanced by convolutional neural networks facilitates clinical interpretation of disease relevant variants in non-coding regulatory elements [STARR-RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263335)
- [GSE310063 æ†çŠ¶ç—…æ¯’ä»‹å¯¼çš„å†ˆæ¯”äºšæŒ‰èšŠé›Œæ€§ç»†èƒä¸­é›„æ€§åŸºå› çš„è¡¨è¾¾ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310063)
- [GSE307420 EVT0185 å¯¹ä¹™é…°è¾…é…¶Aä»£è°¢é…¶çš„æŠ‘åˆ¶ä½œç”¨å¯æŸå®³è‚æ˜ŸçŠ¶ç»†èƒæ´»åŒ–ï¼Œå¹¶é€†è½¬å°é¼ æ¨¡å‹ä¸­çš„ MASH å’Œçº¤ç»´åŒ–ã€‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307420)
- [GSE301764ï¼šä¸€é¡¹æ— åå€šçš„å…¨åŸºå› ç»„å¼€æ”¾é˜…è¯»æ¡†è¿‡è¡¨è¾¾ç­›é€‰é‰´å®šå‡ºB3GALT2ï¼Œä¸€ç§æ–°å‹çš„ç»†èƒASOæ´»æ€§è¯±å¯¼å› å­](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE301764)
- [GSE298237 å¹¼ç¨šæ ·è®°å¿†Tç»†èƒçš„ä»£è°¢é™æ­¢çŠ¶æ€å…ˆäºå¹¶ç»´æŒæŠ—åŸç‰¹å¼‚æ€§Tç»†èƒè®°å¿†](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298237)
- [GSE294955 ZFTA-RELA å®¤ç®¡è†œç˜¤äº§ç”Ÿè¡£åº·é…¸ä½œä¸ºç™Œä»£è°¢ç‰©ä»¥ç»´æŒè‡´ç—…èåˆè¡¨è¾¾ [ChIP-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294955)
- [GSE294954 ZFTA-RELA å®¤ç®¡è†œç˜¤äº§ç”Ÿè¡£åº·é…¸ä½œä¸ºè‡´ç™Œä»£è°¢ç‰©ä»¥ç»´æŒè‡´ç—…èåˆè¡¨è¾¾ [ATAC-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294954)
- [GSE287905 BPTF é€šè¿‡å¢å¼ºæŸ“è‰²è´¨å¯åŠæ€§å’Œç¨³å®š AR-FOXA1 ç›¸äº’ä½œç”¨æ¥è°ƒèŠ‚é›„æ¿€ç´ å—ä½“æ´»æ€§ [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287905)
- [GSE287901 BPTF é€šè¿‡å¢å¼ºæŸ“è‰²è´¨å¯åŠæ€§å’Œç¨³å®š AR-FOXA1 ç›¸äº’ä½œç”¨æ¥è°ƒèŠ‚é›„æ¿€ç´ å—ä½“æ´»æ€§ [ATAC-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287901)
- [GSE276076 å·¨å‹ç—…æ¯’åˆ›é€ äºšç»†èƒç¯å¢ƒä»¥å…‹æœå¯†ç å­-tRNA é”™é… [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276076)
- [GSE310178 æœè‡ OSC åŸºå› ç»„ï¼šè½¬åº§å­å’Œ piRNA ç”Ÿç‰©å­¦ç ”ç©¶èµ„æº [smallRNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310178)
- [GSE310177 æœè‡ OSC åŸºå› ç»„ï¼šè½¬åº§å­å’Œ piRNA ç”Ÿç‰©å­¦ç ”ç©¶èµ„æº [PRO-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310177)
- [GSE310174 æœè‡ OSC åŸºå› ç»„ï¼šè½¬åº§å­å’Œ piRNA ç”Ÿç‰©å­¦ç ”ç©¶èµ„æº [HiC]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310174)
- [GSE310097 LsrL è°ƒèŠ‚ Lsr2 è¯±å¯¼çš„æŸ“è‰²è´¨ç»“æ„ä»¥è°ƒèŠ‚å§”å†…ç‘æ‹‰é“¾éœ‰èŒä¸­çš„ç”Ÿç‰©åˆæˆåŸºå› ç°‡è°ƒæ§ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310097)
- [GSE304800 èƒ†æ±é…¸é€šè¿‡å¯¹è„‚è‚ªé…¸å¸æ”¶çš„é€‰æ‹©æ€§ä½œç”¨æ¥è°ƒèŠ‚è„‚è´¨ä»£è°¢](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304800)
- [GSE293705 19å·æŸ“è‰²ä½“miRNAç°‡ä¿æŠ¤æ»‹å…»å±‚ç»†èƒå…å—è¿‡åº¦æ´»è·ƒçš„å…ˆå¤©å…ç–«ååº”](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293705)
- [GSE280504 NAT10 é€šè¿‡æŸ“è‰²è´¨ç›¸å…³ tRNA è°ƒèŠ‚ p300/CBP æ´»æ€§æ¥ä¿ƒè¿›ç™Œç—‡è½¬ç§» [RNA-ChIP]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280504)
- [GSE279482 Nrf2 åè°ƒè¡¨è§‚é—ä¼ è°ƒæ§ï¼Œå¹¶åœ¨ç ·è¯±å¯¼çš„ç»†èƒè½¬åŒ–è¿‡ç¨‹ä¸­ä½œä¸º KLF4 è¡¨è¾¾å’Œæ´»æ€§çš„ä¸»è°ƒæ§å› å­](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279482)
- [GSE268723 p53 ä»‹å¯¼ç£·è„‚å¤´éƒ¨åŸºå›¢æ¸…é™¤ [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268723)
- [GSE268722 p53 ä»‹å¯¼ç£·è„‚å¤´éƒ¨åŸºå›¢æ¸…é™¤ [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE268722)
- [GSE255610 å®šåˆ¶åŸºäº CRISPR/Cas çš„è¡¨è§‚åŸºå› ç»„ç¼–è¾‘å™¨ä»¥å®ç°å¯ç¼–ç¨‹æŸ“è‰²è´¨é…°åŒ–å¹¶é™ä½ç»†èƒæ¯’æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255610)
- [GSE250430 NAT10 é€šè¿‡æŸ“è‰²è´¨ç›¸å…³ tRNA è°ƒèŠ‚ p300/CBP æ´»æ€§ï¼Œä»è€Œä¿ƒè¿›ç™Œç—‡è½¬ç§»](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE250430)
- [GSE228745 HOXB13 é€šè¿‡ä¸ SWI/SNF å¤åˆç‰©çš„ç›¸äº’ä½œç”¨æ”¹å˜å‰åˆ—è…ºç™Œä¸­çš„æŸ“è‰²è´¨å¯åŠæ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228745)
- [GSE271715 åˆ©ç”¨éšå½¢RNAè½½ä½“ç”Ÿæˆå€­é»‘çŒ©çŒ©è¯±å¯¼å¤šèƒ½å¹²ç»†èƒå¹¶è¿›è¡Œè½¬å½•ç»„åˆ†æï¼šä¸€é¡¹ä¸äººç±»å’Œé»‘çŒ©çŒ©çš„ä¸‰æ–¹æ¯”è¾ƒç ”ç©¶](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE271715)
- [GSE254894 Netrin-1 é€šè¿‡ PPAR(Î³) ä¾èµ–æ€§ WNT-catenin(Î²) ä¿¡å·é€šè·¯è°ƒæ§é«˜è„‚é¥®é£Ÿè¯±å¯¼çš„è„‚è‚ªç”Ÿæˆ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE254894)
- [GSE309838 Nascent strand sequencing of U2OS cells](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309838)
- [GSE305332 LincRNA-EPS regulates iron metabolism and osteoclastogenesis under inflammatory micro-environment](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305332)
- [GSE290662 MYC-FACT Interactions Drive Z-DNA Formation to Modulate Transcriptional Dynamics [ChIP-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290662)
- [GSE290661 MYC-FACT Interactions Drive Z-DNA Formation to Modulate Transcriptional Dynamics [RNA-seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290661)
- [GSE290659 MYC-FACT Interactions Drive Z-DNA Formation to Modulate Transcriptional Dynamics [RNA-seq CC & CL]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290659)
- [GSE278811 EZHIP-mediated PRC2 inhibition is required to maintain H3K27me3-dependent imprinting post fertilization [ChIP-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278811)
- [GSE218454 RNA-seq of B16F10 tongue xenografts with or without inhibition of LN-innervating nociceptive nerves](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE218454)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-18 21:51*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*